Adam R. Craig - 12 Sep 2022 Form 4 Insider Report for CTI BIOPHARMA CORP

Role
President and CEO, Director
Signature
/s/ Bruce J. Seeley, attorney-in-fact for Adam R. Craig
Issuer symbol
N/A
Transactions as of
12 Sep 2022
Net transactions value
-$1,354,190
Form type
4
Filing time
14 Sep 2022, 16:35:33 UTC
Previous filing
16 Aug 2022
Next filing
14 Nov 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTIC Common Stock Options Exercise $203,799 +242,300 +870% $0.8411* 270,161 12 Sep 2022 Direct
transaction CTIC Common Stock Sale $1,557,989 -242,300 -90% $6.43 27,861 12 Sep 2022 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTIC Non-Qualified Stock Option (right to buy) Options Exercise $0 -242,300 -21% $0.000000 913,254 12 Sep 2022 Common Stock 242,300 $0.8411 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was effected pursuant to a 10b5-1 sales plan adopted by the reporting person.
F2 The reporting person's sale of common stock reported herein may be deemed to be matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, to the extent of 5,000 shares of common stock purchased by the reporting person on August 16, 2022. The reporting person has sent to the Issuer the full amount of the disgorgeable profit arising from the sale reported herein.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.27 to $6.58, inclusive. The reporting person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
F4 One third of the shares underlying the option vested on 2/19/2020 and annually thereafter until all the underlying shares were fully vested on 2/19/2022.